New Survey by Neurocrine Biosciences Highlights INGREZZA's Impact on Life Quality for Tardive Dyskinesia Patients

Neurocrine Biosciences Reveals New Survey Findings on Tardive Dyskinesia

Recently, Neurocrine Biosciences, Inc. disclosed the results of a pivotal survey that sheds light on the effectiveness of INGREZZA® (valbenazine) capsules in helping adults with tardive dyskinesia (TD) reduce disruptions to their daily lives. Conducted by Ipsos, this study highlights significant reductions in missed work and school days post-treatment with INGREZZA.

Key Findings from the Survey

The survey, executed between January 15 and February 17, 2026, included responses from 100 participants, 70 of whom were diagnosed with TD. It revealed a striking decrease in disruptions to work or school—from 57% of respondents reporting disturbances prior to treatment to just 21% after beginning treatment with INGREZZA. Additionally, the average number of missed days per month plummeted from 5.6 to only 2.0, underscoring the medication's role in enhancing productivity and daily functionality.

The feedback from patients demonstrated a significant shift in their sentiments regarding social and professional engagement. Before the treatment, 68% of those surveyed reported feeling self-conscious about their condition in work or school settings. This figure dropped to 35% after regular use of INGREZZA, reflecting an improvement not only in physical symptoms but also in emotional well-being.

Enhanced Quality of Life with INGREZZA

The results from the survey indicate that 51% of respondents experienced enhanced productivity in their roles after treatment. Overall, a remarkable 94% of the broader group strongly agreed that treatment with VMAT2 inhibitors like INGREZZA led to improvements in their quality of life and daily activities. These findings are crucial as they assert that managing TD symptoms effectively allows individuals to regain control over their daily interactions and responsibilities.

KINECT-PRO Study Insights

In parallel to the survey, Neurocrine presented findings from the KINECT-PRO™ Phase 4 study, which corroborated the survey's outcomes. This research revealed that among participants who had been taking INGREZZA, a considerable 82.2% reported notable improvements in their TD symptoms, measured with the Tardive Dyskinesia Impact Scale (TDIS). The TDIS is a unique tool developed specifically for assessing the impact of TD from the patient's perspective.

About Tardive Dyskinesia

Tardive dyskinesia, which affects an estimated 800,000 adults in the U.S., manifests through uncontrollable movements and can severely disrupt patients' personal and professional lives. Its symptoms are commonly associated with long-term use of certain antipsychotic medications. INGREZZA, approved specifically for the treatment of TD, hones in on reducing these involuntary movements while allowing patients to regain their independence and improve their quality of life significantly.

Conclusion

This survey underscores the crucial advancements made possible through the use of INGREZZA, marking a significant step forward in treatment for those suffering from tardive dyskinesia. As Neurocrine Biosciences prepares to share these results at the Neuroscience Education Institute Fall Congress 2026, the importance of raising awareness about TD and the available treatment options remains paramount.

Patients can take heart in knowing there are viable paths to improve their conditions and restore normalcy in their lives, both at work and at home. With treatments like INGREZZA, the hope is to diminish the shadows that TD casts over their daily experiences.